Ixico
IXICO plc is a London-based, AIM-listed imaging contract research organization (iCRO) that provides AI-enabled neuroimaging and biomarker analytics services to global biopharma and biotech companies conducting clinical trials in Alzheimer's, Huntington's, Parkinson's and other neurological diseases.
- Company typePublic
- Founded2004
- HeadquartersLondon, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Ixico does
IXICO plc is a London-headquartered, AIM-listed imaging contract research organization (iCRO) specializing in neurological disease clinical trials, with a 20-year operational track record serving global biopharmaceutical companies, biotechs, scientific consortia and non-profits. The company combines clinical trial operations with proprietary AI-enabled neuroimaging technology built around two core assets: the IXI Platform, an AI-driven neuroimaging data management and analysis platform purpose-built for neurological indications, and IXIQ.Ai, a deep-learning brain segmentation engine that has been validated against gold-standard semi-manual methods (such as the Boundary Shift Integral) for measuring brain atrophy in Huntington's, Alzheimer's, Parkinson's and Multiple Sclerosis trials. IXICO's service portfolio includes imaging biomarkers (radiological reads, volumetric MRI, PET/SPECT, advanced MRI techniques such as neuromelanin-sensitive imaging), trial management, data analytics, post-marketing surveillance, and consultancy. The company is pursuing a strategic transition from project-based service contracts toward a 'TechBio' platform-licensing model, including a non-exclusive technology collaboration with Medidata (Dassault Systèmes) integrating IXI with Medidata's clinical trial platform, active participation in consortia such as the Global Alzheimer's Platform Foundation's Bio-Hermes-002 study alongside Sanofi, Biogen, Eli Lilly and Roche, and pursuit of FDA Software-as-Medical-Device approval. Revenue for FY2024-25 was £6.5M (13% YoY growth), with H1 FY2026 revenue of £3.9M (23% YoY growth) and an order book of £18.1M (38% YoY growth) providing strong forward visibility. The company holds ISO/IEC 27001 and ISO 13485 certifications and operates from London with a US subsidiary (IXICO Technologies Inc).
Ixico firmographics
Firmographics- Name
- Ixico
- Legal name
- IXICO plc
- Website
- https://ixico.com
- Company type
- Public
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- IXICO plc is a London-based, AIM-listed imaging contract research organization (iCRO) that provides AI-enabled neuroimaging and biomarker analytics services to global biopharma and biotech companies conducting clinical trials in Alzheimer's, Huntington's, Parkinson's and other neurological diseases.
- Ownership category
- akta.pro rank
Ixico industry classification
Industry- Product category
- Clinical Trial Neuroimaging Analytics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Medical Imaging AI (HDAAAEAH)
Keywords
Where Ixico is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Ixico business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Clinical Trial Imaging Services: IXICO generates revenue by providing neuroimaging and biomarker analytics services to biopharma companies conducting clinical trials in neurological disorders. Revenue is derived from project-based service contracts for imaging analysis, trial management, and consultancy services. H1 2026 revenues of £3.9 million represent 23% growth, driven by new contract wins, contract extensions with existing clients, increased biomarker analysis activity, and expansion into later-stage clinical trials.
- Platform Licensing (Strategic Transition): IXICO is executing a strategic transition from service-based contract model to a proprietary AI platform, licensing its IXI platform to biopharma clients for recurring revenue streams. The goal is to shift from project-based service contracts to a scalable TechBio model where clients license the platform. This includes pursuing FDA approval as a software medical device.
- Blood-Based Biomarker Services: Revenue from blood-based biomarker contracts, including new contract wins and extensions. Examples include £1.2 million total contract win and extension for blood-based biomarker work.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels9 records
Ixico product offering
Product offeringCore offering
IXICO provides AI-enabled neuroimaging and biomarker analytics for clinical trials in neurological diseases. Its proprietary IXI Platform uses deep learning to automate MRI and PET scan analysis (brain atrophy, amyloid detection, hippocampal subfield segmentation) for Alzheimer's, Huntington's, Parkinson's, and Multiple Sclerosis trials. The company operates as an imaging Contract Research Organisation (iCRO), combining the platform with expert clinical trial operations, radiological reads, trial management, and consultancy services for biopharma clients.
Product overview
Ixico operates as a global neuroscience imaging and biomarker analytics company offering an integrated platform-plus-services model. At its core is the IXI Platform, a proprietary AI-enabled neuroimaging technology platform purpose-built for precision medicine in neurological disease clinical trials. The IXI Platform is complemented by IXIQ.Ai, IXICO's deep learning-based brain segmentation technology. Together, these form the technological foundation that powers Ixico's service offerings, which include Imaging Biomarkers (radiological reads, volumetric MRI, PET & SPECT, advanced MRI), Trial Management, Data Analytics, Post-Marketing Surveillance, and Consultancy services. The company serves pharmaceutical and biotech clients across Alzheimer's disease, Huntington's disease, Parkinson's disease, Multiple Sclerosis, and other rare neurological diseases. Ixico also licenses its platform through strategic partnerships such as the Medidata collaboration to generate recurring revenue streams.
Differentiator
Problem solved
Functional benefit
Brands
- IXI Platform: AI-enabled neuroimaging technology platform for precision medicine, purpose-built to drive clinical trial imaging and biomarker science insights in neurological disease research.
- IXIQ.Ai
Products and services
- IXI Platform Proprietary, AI-enabled neuroimaging technology platform for precision medicine, purpose-built to drive clinical trial imaging and biomarker science insights in neurological disease research. Manages global clinical trial data, precisely reads radiological scans, and measures key imaging biomarkers linked to the identification, progression, and treatment of neurological conditions.
- Imaging Biomarkers Services Comprehensive imaging biomarker services including radiological reads, volumetric MRI analysis, PET and SPECT imaging, and advanced MRI techniques (neuromelanin-sensitive MRI, free water imaging, diffusion tensor imaging) for neurological disease clinical trials.
- Trial Management Services Clinical trial management services supporting the design, execution, and oversight of neuroimaging-focused clinical trials, including site management, reader qualification, and regulatory compliance support.
- Data Analytics Services Data analytics services for clinical trial imaging data, including centralised image reading, data standardisation, statistical analysis, and biomarker endpoint selection for neurological disease trials.
- Post-Marketing Surveillance Services Post-marketing surveillance services for monitoring drug safety and efficacy in real-world neurological disease populations using imaging biomarkers.
- Consultancy Services Expert consultancy services in neuroimaging, biomarker strategy, clinical trial design, and regulatory affairs for neurological disease drug development programmes.
Quantifiable outcome
- AI platform sensitivity highest among tested methods for detecting whole brain and caudate volume loss in Huntington's disease studies
- +4 more outcomes
Companies that use Ixico
Customer profileNamed customers7 records
Segments5 records
Ideal customer profiles1 record
Ixico technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability10 records
Feature6 records
Ixico partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- Global Alzheimer's Platform Foundation (GAP)coreStrategic collaboration as partner in Bio-Hermes-002 study, an observational platform evaluating blood-based and digital biomarkers for improving prediction, detection, and diagnosis of Alzheimer's disease. GAP is a non-profit foundation working to reduce the time and cost of Alzheimer's clinical trials. Data from the study is hosted on AD Workbench platform managed by Gates Ventures Alzheimer's Disease Data Initiative.
- SanofiminorJoined as new partner in Bio-Hermes-002 study, analyzing additional biomarkers to augment the study's existing database alongside existing partners Biogen, Eli Lilly, Roche, and others.
- BiogenminorExisting partner in Global Alzheimer's Platform Foundation's Bio-Hermes-002 observational study evaluating blood-based and digital biomarkers for Alzheimer's disease.
- Eli Lilly and CompanyminorExisting partner in Global Alzheimer's Platform Foundation's Bio-Hermes-002 observational study for Alzheimer's disease biomarkers.
- RocheminorExisting partner in Global Alzheimer's Platform Foundation's Bio-Hermes-002 observational study. Roche is also involved in neuromelanin MRI research through the Prasinezumab program.
- Medidata (Dassault Systèmes)coreNon-exclusive technology collaboration aligning IXI Platform with Medidata's clinical trial platform to create a unified neuroimaging data and analysis offering for biopharma clinical trials. Medidata serves 18 of top 25 pharma companies and 90% of global CROs across 140 geographies. The collaboration provides IXICO with expanded scale, technological co-development opportunities, market reach, and an additional commercial route.
- Global Alzheimer's Platform Foundation (GAP) - Bio-Hermes 2 TrialcoreIXICO supporting the Global Alzheimer's Platform Foundation's Bio-Hermes 2 trial, an observational study evaluating blood-based and digital biomarkers alongside imaging for Alzheimer's disease.
- Life Molecular ImagingminorCollaboration agreement focused on advancing neuroimaging capabilities for clinical trials in neurological diseases.
- Huntington's Disease Image Harmonization Consortium (HD-IH)coreConsortium using IXICO's IXIQ.Ai technology to conduct large-scale analysis of brain changes in Huntington's disease. Consortium secured new member and additional funding to complete analysis, further validating IXICO's AI imaging platform.
- Top 5 Global CRO (Unnamed)coreNew imaging master vendor agreement with a top 5 global CRO, providing first contract award for IXIQ.Ai brain imaging technology. This partnership was described as a significant milestone for commercial expansion.
Scale indicators9 records
Recent moves8 records
Expansion highlights6 records
Ixico competitors and assessment
Company assessmentMarket position
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Ixico social profiles
Digital presenceIxico compliance and trust
Trust signalCompliance2 records
Ixico financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ixico leadership team
Management profileNumber of profiles
Profiles8 records
Ixico subsidiaries and ownership
Company hierarchySubsidiaries2 records
Ixico funding detail
Funding detailFunding overview
Funding rounds7 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ixico M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ixico
What does Ixico do?
IXICO provides AI-enabled neuroimaging and biomarker analytics for clinical trials in neurological diseases. Its proprietary IXI Platform uses deep learning to automate MRI and PET scan analysis (brain atrophy, amyloid detection, hippocampal subfield segmentation) for Alzheimer's, Huntington's, Parkinson's, and Multiple Sclerosis trials. The company operates as an imaging Contract Research Organisation (iCRO), combining the platform with expert clinical trial operations, radiological reads, trial management, and consultancy services for biopharma clients.
Is Ixico a public or private company?
Ixico is a public company. It is classified as public and is currently operating.
When was Ixico founded?
Ixico was founded in 2004. It employs 51 to 100 people.
Where is Ixico based?
Ixico is headquartered in London, United Kingdom, in the Europe region.
How does Ixico make money?
Three revenue lines are on record. Clinical Trial Imaging Services are the primary driver. The others are platform Licensing (Strategic Transition) and blood-Based Biomarker Services.
Does Ixico have an API?
No public API is recorded for Ixico.
What industry is Ixico in?
Ixico's product category is Clinical Trial Neuroimaging Analytics. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 621511 and its SIC code is 8731.